Savas, Peter
The University of Melbourne · Peter MacCallum Cancer Centre
6 papers on CoChatORCID 0000-0001-5999-428X
Most cited papers
- Verified
Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Savas, P., Virassamy, B., Ye, C., Salim, A., Mintoff, C. P., Caramia, F., Salgado, R., Byrne, D. J., Teo, Z. L., et al. (2018) · Nature Medicine
Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology
Cited by 992
- Verified
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016) · Nature Reviews Clinical Oncology
Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies
Cited by 890
- Verified
Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade
House, I. G., Savas, P., Lai, J., Chen, A. X. Y., Oliver, A. J., Teo, Z. L., Todd, K. L., Henderson, M. A., Giuffrida, L., Petley, E. V., et al. (2020) · Clinical Cancer Research
Cancer Immunotherapy and BiomarkersChemokine receptors and signaling
Cited by 790
- Verified
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research
Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies
Cited by 536
- Verified
Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer
Teo, Z. L., Versaci, S., Dushyanthen, S., Caramia, F., Savas, P., Mintoff, C. P., Zethoven, M., Virassamy, B., Luen, S. J., McArthur, G. A., et al. (2017) · Cancer Research
Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer
Cited by 196
- Verified
Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
Dushyanthen, S., Teo, Z. L., Caramia, F., Savas, P., Mintoff, C. P., Virassamy, B., Henderson, M. A., Luen, S. J., Mansour, M., Kershaw, M. H., et al. (2017) · Nature Communications
Cancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways
Cited by 124
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free